Redbiotec Collaborates with GE Healthcare Life Sciences on Vaccine Development and Manufacturing

News
Article

Redbiotec and GE Healthcare Life Sciences develop a novel manufacturing process for virus-like particles.

Redbiotec, a Swiss biopharmaceutical company specializing in vaccine development, is collaborating with GE Healthcare Life Sciences to develop and produce vaccines against cytomegalovirus (CMV), a common virus in the herpes family of viruses. Using GE Healthcare's single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a novel process for the production, clarification, and concentration of CMV-like particles.

Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. This technology is used to support the company’s mission to discover and develop vaccines against the highly prevalent influenza and herpes viruses.

Source: Redbiotec

Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content